on Quantum Genomics (EPA:ALQGC)
Quantum Genomics: Publication of 2024 annual accounts and strategic developments
Quantum Genomics, listed on Euronext Growth, has published its financial results for 2024, showing zero revenue and a net loss of €8.9 million. Facing financial difficulties, the company saw its shareholders' equity fall from €436,664 in 2023 to -€2,455,941 in 2024. Its cash position stands at €301,018, insufficient to ensure continued operations beyond four months without additional fundraising.
At the same time, the company announced a change in its listing sponsor, moving from Allegra Finance to EuroLand Corporate. Trading in its shares has been suspended since October 2024 due to a proposed reverse acquisition not yet approved by Euronext. Quantum Genomics hopes to resume trading in the future, with merger plans underway, although there is no set timeline.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Quantum Genomics news